Skip to content
Start free

Sun Pharmaceutical Industries Ltd.

NSE: SUNPHARMAHealthcareDrug Manufacturers - Specialty & Generic

Last close
₹1,760.00
Day change
+₹0.20 (+0.01%)vs
Market cap
₹4.32 lakh crIndian rupees
Research updated
1 report
Follow Sun Pharmaceutical Industries

Share this file

About Sun Pharmaceutical Industries

Sun Pharmaceutical Industries Ltd. is a major player in the global pharmaceutical industry, specializing in the manufacturing and marketing of a broad array of pharmaceutical formulations and active pharmaceutical ingredients. The company's primary function is to develop generic drugs and specialty products in areas such as cardiology, psychiatry, neurology, gastroenterology, and anti-infectives. Known for its strong R&D focus, Sun Pharma has positioned itself as a leader in several therapeutic segments and continues to expand its presence worldwide through strategic acquisitions and partnerships. The company has a notable impact on the generic markets in North America, India, and emerging economies. Sun Pharma's significance in the financial market stems from its wide-ranging product portfolio and global reach, making it a vital component of the healthcare sector. Headquartered in Mumbai, India, and founded in 1983, the company plays a crucial role in providing affordable medication to millions, contributing significantly to public health improvement and market growth.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Listing
NSE: SUNPHARMA
Employees
47,000
Headquarters
Mumbai, India
ISIN
INE044A01036
Website
sunpharma.com

Public research

The latest report on Sun Pharmaceutical Industries opens with Individual or above

Mool’s latest report on Sun Pharmaceutical Industries, of 3 Oct 2026, has no section published on the open web.

With Individual or above

What the full research on Sun Pharmaceutical Industries includes

Every piece of Mool’s research is built the same way: a researched evidence base, analyses that build on each other, a research model and a report with the call.

The report and Mool’s call

  • The 12-month rating and target
  • The 3-month view
  • Mool's estimates beside the street's
  • The claims the view rests on, and what would change it

The analyses, among them

  • Business model & financial foundationWhat the company does and how it makes money, its structure, five years of financials and the metrics that matter for it.
  • Future earnings & financial modelForecasts built from the drivers that move the business, by scenario, beside the street's.
  • Fundamental valuation & 12-month thesisWhat the business is worth on several methods, what the market already prices in and the 12-month thesis that follows.

The research model

The model behind the report: the company’s history, the drivers that move it, its forecasts by scenario and the valuation the 12-month target comes from.

See Mool’s call and the full research

Individual or above opens every piece of research Mool has published. A new account can start with 10 days of Pro, or of Firm on a work email address. No card needed.

Report history

Reports on Sun Pharmaceutical Industries

  1. Research reportLatest

Same sector

All Healthcare companies

  • Divi's Laboratories Ltd.

    NSE: DIVISLAB

    Healthcare · Drug Manufacturers - Specialty & Generic

    ₹9,340.00 last close on 9 Oct 2026 −0.22%

    Research updated

  • Torrent Pharmaceuticals Ltd.

    NSE: TORNTPHARM

    Healthcare · Drug Manufacturers - Specialty & Generic

    ₹4,656.90 last close on 9 Oct 2026 +0.86%

    Research updated

  • Zydus Lifesciences Ltd.

    NSE: ZYDUSLIFE

    Healthcare · Drug Manufacturers - Specialty & Generic

    ₹1,117.50 last close on 9 Oct 2026 +0.49%

    Research updated

  • Lenskart Solutions Limited

    NSE: LENSKART

    Healthcare · Medical Instruments & Supplies

    ₹677.65 last close on 9 Oct 2026 +3.62%

    Research updated

  • Emcure Pharmaceuticals Ltd.

    NSE: EMCURE

    Healthcare · Drug Manufacturers - Specialty & Generic

    ₹1,833.50 last close on 9 Oct 2026 −0.97%

    Research updated

Prices are the last close on the NSE, 9 Oct 2026. Research from Mool’s report of 3 Oct 2026; page updated 12 Oct 2026.

Mool’s research is written by AI agents and published by Mool Capital Private Limited, a SEBI-registered Research Analyst, registration INH000012449, which is responsible for it. This page shows factual company information; it carries no rating and is not investment advice for any individual. Investment in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Read the disclosures.